Bromide

Bromide

SCHEMBL3921022

Cc1cc[n+](CCCCCC(=O)O)cc1.[Br-]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 7/20 0.43
HTT P42858 1/20 0.56
MEN1 O00255 1/20 0.46
APAF1 O14727 1/20 0.46
RGS12 O14924 1/20 0.46
HSP90AA1 P07900 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
BCHE P06276 7/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
PMP22 Q01453 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1105692 0.98 HTT (0.58) HTTMEN1APAF1RGS12HSP90AA1
SCHEMBL14454728 0.96 HTT (0.55) HTTMEN1APAF1RGS12HSP90AA1
SCHEMBL13464660 0.91 HTT (0.52) HTTMAPK1KMT2ATSHR
SCHEMBL13464661 0.83 KMT2A (0.48) HTTMEN1KMT2ALMNATSHR
Bromide SCHEMBL30903821 0.82 HTT (0.78) HTTMEN1KMT2ABCHEACHE
SCHEMBL13556906 0.81 MAPT (0.50) HTTMEN1APAF1RGS12HSP90AA1
Azelaic Acid SCHEMBL3807504 0.80 TSHR (0.60) MEN1KMT2ALMNATSHRNFKB1
P-Xylene SCHEMBL36101 0.80 TSHR (0.60) MEN1KMT2ALMNATSHRNFKB1
Sebacic Acid SCHEMBL36102 0.80 TSHR (0.60) MEN1KMT2ALMNATSHRNFKB1
Sebacic Acid SCHEMBL28279615 0.80 TSHR (0.60) MEN1KMT2ALMNATSHRNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186600-A1 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS COMERA LIFE SCIENCES, INC. 2025-06-12 US disclosed
US-20230270864-A1 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS COMERA LIFE SCIENCES, INC. 2023-08-31 US disclosed
EP-4210757-A2 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS Comera Life Sciences, Inc. (US) 2023-07-19 EP disclosed
US-20230027396-A1 EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS COMERA LIFE SCIENCES, INC. 2023-01-26 US disclosed
US-20220401559-A1 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS COMERA LIFE SCIENCES, INC. 2022-12-22 US disclosed
WO-2022056220-A2 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS REFORM BIOLOGICS, INC. (US) 2022-03-17 WO disclosed
US-20220062423-A1 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS COMERA LIFE SCIENCES, INC. 2022-03-03 US disclosed
EP-3886909-A1 EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING ReForm Biologics, Inc. (US) 2021-10-06 EP disclosed
US-20210113697-A1 EXCIPIENT COMPOUNDS FOR PROTEIN FORMULATIONS COMERA LIFE SCIENCES, INC. 2021-04-22 US disclosed
WO-2020112855-A1 EXCIPIENT COMPOUNDS FOR PROTEIN PROCESSING REFORM BIOLOGICS, LLC (US) 2020-06-04 WO disclosed
US-7563907-B2 Compounds based on polymethines DYOMICS GMBH (DE) 2009-07-21 US disclosed
US-20040260093-A1 Compound, especially marker-dye on the basis of polymethines DYOMICS GMBH (DE) 2004-12-23 US disclosed
EP-1318177-B1 Compound, in particular marker-dye, based on polymethines DYOMICS GMBH (DE) 2004-09-22 EP disclosed
US-20030165942-A1 Compound, especially marker-dye, on the basis of polymethines DYOMICS GMBH (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030165942-A1 Compound, especially marker-dye, on the basis of polymethines MKI67, CYBA, IK ACHE 1739/4885HTT 2692/4885MEN1 2072/4885
US-20040260093-A1 Compound, especially marker-dye on the basis of polymethines MKI67, IK, CYBA ACHE 1959/4885HTT 2664/4885MEN1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.